UPDATE: Jefferies Raises PT to $105 on Medivation on Zytiga Data

Loading...
Loading...
Jefferies reiterates its Buy rating on Medivation
MDVN
and raises its price target from $97 to $105. Jefferies notes, "On Saturday morning at ASCO, Dr. Charles Ryan from UCSF presented Ph III data reporting a strong OS benefit with Zytiga (~9 mos benefit if 33% improvement from 27 mos) in 1,088 chemo-naïve patients with CRPC. As a result of enzalutamide's broader AR inhibitory activity v. Zytiga, we believe enza could meet/beat the OS benefit observed in the '302 trial." MDVN closed at $82.68 on Friday.
Posted In: Analyst ColorPrice TargetReiterationPre-Market OutlookAnalyst RatingsJefferies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...